– ISRAEL, Jerusalem – Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of David Fox to its board of directors as an independent member.
Mr. Fox brings significant leadership, company-building and business development experience to Gamida Cell’s board of directors as the company advances its clinical development candidates: omidubicel, advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of bone marrow transplant, and GDA-201, an investigational, natural killer cell-based cancer immunotherapy in Phase 1 development in patients with non-Hodgkin lymphoma.
“We are pleased to welcome David to our Board of Directors,” said Dr Julian Adams, CEO. “David has expertise fostering culture at growing, global organizations and executing strategic partnerships. His insights will be invaluable as we work to maximize the potential of our clinical programs and bring potentially curative cell therapies to patients.”
About David Fox
Mr. Fox was most recently a partner at Kirkland & Ellis LLP and served as a member of its Global Executive Management Committee. Mr. Fox is a director of Israel Discount Bank of New York, a member of the board of directors at the Park Avenue Armory, and a member of the advisory board of New Alternatives for Children. In addition, Mr. Fox is on the board of governors and an honorary fellow of the Hebrew University, Jerusalem.
“I’m excited to join Gamida Cell’s board of directors,” said Mr. Fox. “Gamida Cell is at an exciting point in its trajectory. Recent Phase 3 data has demonstrated that omidubicel has the potential to provide a new standard of care in bone marrow transplant, and GDA-201 has demonstrated compelling clinical activity in patients with lymphoma. I look forward to working with Gamida Cell to achieve its goals as the company enters its next phase of growth.”
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.
For more information: https://www.gamida-cell.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
